{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T03:11:07Z","timestamp":1785726667372,"version":"3.56.0"},"reference-count":46,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2025,5,19]]},"DOI":"10.18632\/oncotarget.28723","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T14:33:59Z","timestamp":1747665239000},"page":"337-346","source":"Crossref","is-referenced-by-count":6,"title":["Advancements in bladder cancer treatment: The synergy of radiation and immunotherapy"],"prefix":"10.18632","volume":"16","author":[{"given":"Nazmul","family":"Hasan","sequence":"first","affiliation":[{"name":"Department of Medicine, University of California, Irvine, CA 92868, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, Irvine, CA 92868, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer","family":"Gibson","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, Irvine, CA 92868, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbod","family":"Khaleghi","sequence":"additional","affiliation":[{"name":"Chao Family Comprehensive Cancer Center, Division of Hematology and Oncology, University of California, Irvine, CA 92868, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozhan","family":"Ziari","sequence":"additional","affiliation":[{"name":"Chao Family Comprehensive Cancer Center, Division of Hematology and Oncology, University of California, Irvine, CA 92868, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash Rezazadeh","family":"Kalebasty","sequence":"additional","affiliation":[{"name":"Chao Family Comprehensive Cancer Center, Division of Hematology and Oncology, University of California, Irvine, CA 92868, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"7","author":"Jemal","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"2","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1177\/107327480000700401","article-title":"Molecular mechanisms and pathways in bladder cancer development and progression","volume":"7","author":"Messing","year":"2000","journal-title":"Cancer Control"},{"key":"3","first-page":"1106","article-title":"Bladder histological changes associated with chronic indwelling urinary catheter","volume":"16","author":"Dmochowski","year":"1999","journal-title":"J Urol"},{"key":"4","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1053\/apmr.2002.29653","article-title":"Excess risk of bladder cancer in spinal cord injury: evidence for an association between indwelling catheter use and bladder cancer","volume":"8","author":"Hamman","year":"2002","journal-title":"Arch Phys Med Rehabil"},{"key":"5","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1001\/jama.2011.1142","article-title":"Association between smoking and risk of bladder cancer among men and women","volume":"30","author":"Abnet","year":"2011","journal-title":"JAMA"},{"key":"6","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.eururo.2015.06.042","article-title":"The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks","volume":"7","author":"La Vecchia","year":"2016","journal-title":"Eur Urol"},{"key":"7","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.eururo.2023.03.029","article-title":"Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors","volume":"8","author":"Panebianco","year":"2023","journal-title":"Eur Urol"},{"key":"8","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/ncpuro0510","article-title":"Mechanisms of disease: The epidemiology of bladder cancer","volume":"3","author":"La Vecchia","year":"2006","journal-title":"Nat Clin Pract Urol"},{"key":"9","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.1200\/JCO.2012.43.2278","article-title":"Risks of less common cancers in proven mutation carriers with lynch syndrome","volume":"3","author":"Moeslein","year":"2012","journal-title":"J Clin Oncol"},{"key":"10","volume-title":"StatPearls","author":"Aeddula","year":"2024"},{"key":"11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40779-022-00406-y","article-title":"Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition)","volume":"9","author":"Li","year":"2022","journal-title":"Mil Med Res"},{"key":"12","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"2","author":"Konety","year":"2021","journal-title":"Lancet Oncol"},{"key":"13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.currproblcancer.2014.06.001","article-title":"Multimodal management of muscle-invasive bladder cancer","volume":"3","author":"Apolo","year":"2014","journal-title":"Curr Probl Cancer"},{"key":"14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ucl.2015.02.002","article-title":"Trimodality therapy in bladder cancer: who, what, and when?","volume":"4","author":"Citrin","year":"2015","journal-title":"Urol Clin North Am"},{"key":"15","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Bladder cancer (Version 1.2024). 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf."},{"key":"16","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","volume":"39","author":"Li","year":"2024","journal-title":"N Engl J Med"},{"key":"17","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma","volume":"38","author":"Enting","year":"2021","journal-title":"N Engl J Med"},{"key":"18","doi-asserted-by":"publisher","first-page":"3849","DOI":"10.1002\/jcp.29279","article-title":"Multi-omics analysis of tumor mutation burden combined with immune infiltrates in bladder urothelial carcinoma","volume":"23","author":"Luo","year":"2020","journal-title":"J Cell Physiol"},{"key":"19","doi-asserted-by":"publisher","first-page":"970885","DOI":"10.3389\/fimmu.2022.970885","article-title":"Immune landscape of distinct subtypes in urothelial carcinoma based on immune gene profile","volume":"1","author":"Peng","year":"2022","journal-title":"Front Immunol"},{"key":"20","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.urolonc.2021.01.013","article-title":"Surgical challenges and considerations in Tri-modal therapy for muscle invasive bladder cancer","volume":"4","author":"Kassouf","year":"2022","journal-title":"Urol Oncol"},{"key":"21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00345-023-04744-x","article-title":"Radiotherapy in metastatic bladder cancer","volume":"4","author":"Maitre","year":"2024","journal-title":"World J Urol"},{"key":"22","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.2174\/092986712800099811","article-title":"Induction of abscopal anti-tumor immunity and immunogenic tumor cell death by ionizing irradiation - implications for cancer therapies","volume":"1","author":"Gaipl","year":"2012","journal-title":"Curr Med Chem"},{"key":"23","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.trecan.2016.09.007","article-title":"Immune Priming of the Tumor Microenvironment by Radiation","volume":"2","author":"Hahn","year":"2016","journal-title":"Trends Cancer"},{"key":"24","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1038\/bjc.2013.117","article-title":"Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer","volume":"10","author":"Peggs","year":"2013","journal-title":"Br J Cancer"},{"key":"25","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","article-title":"Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer","volume":"4","author":"Cheng","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"26","doi-asserted-by":"publisher","first-page":"4227","DOI":"10.3390\/cancers15174227","article-title":"Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma","volume":"1","author":"Uemura","year":"2023","journal-title":"Cancers (Basel)"},{"key":"27","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway","volume":"37","author":"Boussiotis","year":"2016","journal-title":"N Engl J Med"},{"key":"28","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1084\/jem.20082492","article-title":"Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies","volume":"20","author":"Allison","year":"2009","journal-title":"J Exp Med"},{"key":"29","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1172\/JCI69219","article-title":"Radiation and immunotherapy: a synergistic combination","volume":"12","author":"Vapiwala","year":"2013","journal-title":"J Clin Invest"},{"key":"30","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3389\/fphar.2018.00185","article-title":"Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions","volume":"9","author":"Lin","year":"2018","journal-title":"Front Pharmacol"},{"key":"31","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1158\/1535-7163.MCT-18-0986","article-title":"PD-1\/PD-L1 Immune Checkpoint Inhibition with Radiation in Bladder Cancer:and Abscopal Effects","volume":"1","author":"Kassouf","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"32","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s00262-023-03376-9","article-title":"Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer","volume":"7","author":"Stec","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"33","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1080\/21645515.2020.1840254","article-title":"Effect of radiotherapy on T cell and PD-1 \/ PD-L1 blocking therapy in tumor microenvironment","volume":"1","author":"Cui","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"34","doi-asserted-by":"publisher","first-page":"e006551","DOI":"10.1136\/jitc-2022-006551","article-title":"Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023","volume":"1","author":"Zheng","year":"2023","journal-title":"J Immunother Cancer"},{"key":"35","doi-asserted-by":"publisher","first-page":"e938","DOI":"10.1097\/JU.0000000000000936.08","article-title":"MP61-08: A phase I\/II trial of transurethral surgery followed by a combination of atezolizumab, an anti-PD-L1 (MPDL3280A), with trimodal therapy in patients with muscle-invasive bladder cancer","volume":"20","author":"Vanhuyse","year":"2020","journal-title":"J Urol"},{"key":"36","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.ijrobp.2018.04.070","article-title":"Dose-limiting Urinary Toxicity With Pembrolizumab Combined With Weekly Hypofractionated Radiation Therapy in Bladder Cancer","volume":"10","author":"Huddart","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"37","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1200\/JCO.2020.38.15_suppl","article-title":"Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy as bladder-sparing therapy in patients with localized muscle invasive bladder cancer: A SOGUG study","author":"Garcia del Muro","year":"2020","journal-title":"J Clin Oncol"},{"key":"38","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1200\/JCO.2021.39.6_suppl.428","article-title":"INTACT (S\/N1806) phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle-invasive bladder cancer: Safety update on first 73 patients","volume":"3","author":"Lerner","year":"2021","journal-title":"J Clin Oncol"},{"key":"39","doi-asserted-by":"publisher","first-page":"TPS605","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS605","article-title":"NEXT: A phase II, open-label study of nivolumab adjuvant to chemoradiation in patients (pts) with localized muscle invasive bladder cancer","volume":"3","author":"Agarwal","year":"2020","journal-title":"J Clin Oncol"},{"key":"40","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1200\/JCO.2024.42.4_suppl.612","article-title":"NEXT: A phase 2 study of nivolumab adjuvant to chemoradiation in patients (pts) with localized urothelial carcinoma","volume":"4","author":"Gupta","year":"2024","journal-title":"J Clin Oncol"},{"key":"41","doi-asserted-by":"publisher","first-page":"8360","DOI":"10.1038\/s41598-018-26089-x","article-title":"Oncological outcomes, quality of life outcomes and complications of partial cystectomy for selected cases of muscle-invasive bladder cancer","volume":"8","author":"Kempkensteffen","year":"2018","journal-title":"Sci Rep"},{"key":"42","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.euo.2023.09.011","article-title":"Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502)","volume":"7","author":"Hruby","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"43","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s00345-020-03440-4","article-title":"Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response","volume":"3","author":"Sargos","year":"2021","journal-title":"World J Urol"},{"key":"44","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"3","author":"Fecher","year":"2021","journal-title":"J Clin Oncol"},{"key":"45","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ccell.2022.02.015","article-title":"A composite T cell biomarker in pre-treatment blood samples correlates with detection of immune-related adverse events","volume":"4","author":"Sharma","year":"2022","journal-title":"Cancer Cell"},{"key":"46","doi-asserted-by":"publisher","first-page":"663852","DOI":"10.3389\/fonc.2021.663852","article-title":"Immunotherapy Combined With Radiation Therapy for Genitourinary Malignancies","volume":"1","author":"Miyamoto","year":"2021","journal-title":"Front Oncol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28723","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T14:34:02Z","timestamp":1747665242000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,5,19]]}},"alternative-id":["28723"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28723","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]}}}